(Circulation. 2000;101:311.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Nifedipine-Induced Coronary Vasodilation in Ischemic Hearts Is Attributable to Bradykinin- and NO-Dependent Mechanisms in Dogs
From the Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
Correspondence to Masafumi Kitakaze, MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka Prefecture 565-0871, Japan. E-mail kitakaze{at}medone.med.osaka-u.ac.jp
Background—Dihydropyridine calcium channel blockers protect endothelial cells against ischemia and reperfusion injury, suggesting that nifedipine may increase the in vivo cardiac NO level and thus coronary blood flow (CBF) in ischemic hearts. We tested this hypothesis.
Methods and Results—In open-chest dogs, coronary perfusion pressure (CPP) was reduced in the left anterior descending coronary artery so that CBF decreased to one third of the control level, and thereafter CPP was maintained constant (103±8 to 43±3 mm Hg, n=9). We obtained fractional shortening (FS) and lactate extraction ratio (LER) as indices of regional myocardial contraction and metabolism. Both FS (26.4±2.1% to 6.7±2.0%, n=9, P<0.001) and LER (32±6% to -37±5%, n=9, P<0.001) showed a decrease when CPP was reduced. After intracoronary infusion of nifedipine (4 µg · kg-1 · min-1), CBF increased from 30±1 to 48±4 mL · 100 g-1 · min-1 (P<0.01) without a change of CPP (n=9). Both FS (14.0±1.9%, n=9) and LER (-9±7%, n=9) also increased (P<0.01). Nifedipine increased the difference in the level of metabolites of NO (nitrate+nitrite; 9±3 to 25±5 nmol/mL, n=9, P<0.01) and bradykinin (22±5 to 58±4 pmol/mL, n=9, P<0.01) between coronary venous and arterial blood. L-NAME (an NO synthase inhibitor) or HOE-140 (a bradykinin receptor antagonist) attenuated (P<0.05) the increase in CBF (29±3 and 35±2 mL · 100 g-1 · min-1, n=5 each), FS (4.8±0.6% and 6.9±1.7%, n=5 each), LER (-47±8% and -35±9%, n=5 each), and nitrate+nitrite (3±2 and 8±4 nmol/mL, n=5 each) due to nifedipine infusion.
Conclusions—These results indicate that the calcium channel blocker nifedipine mediates coronary vasodilation and improves myocardial ischemia through both bradykinin/NO-dependent and -independent mechanisms.
Key Words: nitric oxide • bradykinin • ischemia • blood flow
This article has been cited by other articles:
 |
|
 |
|
  T. Sugiura, T. Kondo, Y. Kureishi-Bando, Y. Numaguchi, O. Yoshida, Y. Dohi, G. Kimura, R. Ueda, T. J. Rabelink, and T. Murohara Nifedipine Improves Endothelial Function: Role of Endothelial Progenitor Cells Hypertension, September 1, 2008; 52(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lenasi, K. Kohlstedt, B. Fichtlscherer, A. Mulsch, R. Busse, and I. Fleming Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495 Cardiovasc Res, October 1, 2003; 59(4): 844 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Zvara Treatment of Perioperative Myocardial Ischemia Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183. [Abstract] [PDF]
|
|
|
|
|
|
A. Gourine, A. Gonon, P.-O. Sjoquist, and J. Pernow Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium Cardiovasc Res, July 1, 2001; 51(1): 100 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Berkels, G. Egink, T. A. Marsen, H. Bartels, R. Roesen, and W. Klaus Nifedipine Increases Endothelial Nitric Oxide Bioavailability by Antioxidative Mechanisms Hypertension, February 1, 2001; 37(2): 240 - 245. [Abstract] [Full Text] [PDF]
|
|